A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance

Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL

(2012) M Leiva et al.   LEUKEMIA

Hematopoietic Stem Cells Survive Circulation Arrest and Reconstitute Hematopoiesis in Myeloablated Mice

(2011) Jana Michalova et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737

(2011) A. P. Wiegmans et al.   CANCER RESEARCH

PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice

(2011) John S. Welch et al.   JOURNAL OF CLINICAL INVESTIGATION

The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha

(2011) M Occhionorelli et al.   LEUKEMIA

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

(2011) Thomas Robert et al.   NATURE

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer

(2011) Raffaella Di Micco et al.   NATURE CELL BIOLOGY

Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence

(2010) Maurice Reimann et al.   CANCER CELL

Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis

(2010) Roel H Wilting et al.   EMBO JOURNAL

Histone deacetylases and epigenetic therapies of hematological malignancies

(2010) Ciro Mercurio et al.   PHARMACOLOGICAL RESEARCH

Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia

(2009) F. C. Guibal et al.   BLOOD

Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer

(2009) Oronza Antonietta Botrugno et al.   CANCER LETTERS

High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples

(2009) Jacqueline E. Payton et al.   JOURNAL OF CLINICAL INVESTIGATION

PML–RARα initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors

(2009) S Wojiski et al.   LEUKEMIA

Genetic dissection of histone deacetylase requirement in tumor cells

(2009) M. Haberland et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

(2008) Nagma Khan et al.   BIOCHEMICAL JOURNAL

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

(2008) K. F. Whitecross et al.   BLOOD

Histone deacetylase inhibitors and genomic instability

(2008) Grégory Eot-Houllier et al.   CANCER LETTERS

Quantitative Analysis of Histone Deacetylase-1 Selective Histone Modifications by Differential Mass Spectrometry

(2008) Anita Y. H. Lee et al.   JOURNAL OF PROTEOME RESEARCH

MBD3, a Component of the NuRD Complex, Facilitates Chromatin Alteration and Deposition of Epigenetic Marks

(2008) L. Morey et al.   MOLECULAR AND CELLULAR BIOLOGY

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

(2008) Michael Haberland et al.   NATURE REVIEWS GENETICS

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

(2008) Xiang-Jiao Yang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY